Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis

Breast Cancer Research and Treatment

Volumn 157, Issue 3, 2016, Pages 587-596

  Di Meglio, Antonio ^a,b   Freedman, Rachel A ^a   Lin, Nancy U ^a   Barry, William T ^a   Metzger Filho, Otto ^a   Keating, Nancy L ^c,d   King, Tari A ^d   Sertoli, Mario Roberto ^b   Boccardo, Francesco ^b   Winer, Eric P ^a   Vaz Luis, Ines ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Incidence; Invasive ductal carcinoma; Invasive lobular carcinoma; Metastatic breast cancer; Survival

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREND STUDY; TUMOR DIFFERENTIATION; YOUNG ADULT; BREAST TUMOR; CANCER REGISTRY; INCIDENCE; LOBULAR CARCINOMA; METASTASIS; PAGET NIPPLE DISEASE; SURVIVAL ANALYSIS; UNITED STATES;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84975493632     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-3845-5     Document Type: Article

References (32)

1. du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Robertson JF, Blamey RW (1991) An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 17(3):251–257
2. Toikkanen S, Pylkkänen L, Joensuu H (1997) Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 76(9):1234–1240
3. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE (2000) Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 88(11):2561–2569
4. Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93(9):1046–1052. doi:10.1038/sj.bjc.6602787
5. Li CI, Anderson BO, Daling JR, Moe RE (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289(11):1421–1424
6. Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16(12):2773–2780. doi:10.1158/1055-9965.EPI-07-0546
7. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674. doi:10.1056/NEJMsr070105
8. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative I (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333
9. Welch HG, Gorski DH, Albertsen PC (2015) Trends in metastatic breast and prostate cancer-lessons in cancer dynamics. N Engl J Med 373(18):1685–1687. doi:10.1056/NEJMp1510443
10. Bleyer A, Welch HG (2012) Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367(21):1998–2005. doi:10.1056/NEJMoa1206809
11. SEER cancer statistics review, 1975–2012. National Cancer Institute, Bethesda, MD (April 2015) http://seer.cancer.gov/archive/csr/1975_2012/ on November 2014 SEER data submission, posted to the SEER web site
12. Ly BH, Nguyen NP, Vinh-Hung V, Rapiti E, Vlastos G (2010) Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit? Breast Cancer Res Treat 119(3):537–545. doi:10.1007/s10549-009-0610-z
13. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26(30):4891–4898. doi:10.1200/JCO.2007.14.1168
14. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22(16):3302–3308. doi:10.1200/JCO.2004.08.095
15. Surveillance, Epidemiology, and End Results, available at: http://seer.cancer.gov/data/seerstat/nov2011/. Accessed July 2015
16. Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011
17. Greene FL, American Joint Committee on Cancer, American Cancer Society. (2002) AJCC cancer staging handbook: from the AJCC cancer staging manual. 6th edn. Springer, New York
18. Statistical Methodology and Applications Branch SRP, National Cancer Institute: Joinpoint Regression Program, Version 4.2.0, April 2015
19. Sample Joinpoint Regression Analysis, available at: http://surveillance.cancer.gov/joinpoint/example.html. Accessed June 2015
20. Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19(3):335–351
21. Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O’reilly SE, Olivotto IA (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110(5):973–979. doi:10.1002/cncr.22867
22. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100(1):44–52. doi:10.1002/cncr.11859
23. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104(8):1742–1750. doi:10.1002/cncr.21359
24. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, Berlin JA, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Wingo PA, Spirtas R (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95(12):2455–2464. doi:10.1002/cncr.10984
25. Polednak AP (2015) Increase in distant stage breast cancer incidence rates in US women aged 25–49 Years, 2000–2011: the stage migration hypothesis. J Cancer Epidemiol 2015:710106. doi:10.1155/2015/710106
26. Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiowka M, Hewson N, Rukazenkov Y, Robertson JF (2015) Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 33(32):3781–3787. doi:10.1200/JCO.2015.61.5831
27. Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii H, Winer EP, Freedman RA (2015) Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 151(3):697–707. doi:10.1007/s10549-015-3432-1
28. Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, Intra M, Montagna E, Cancello G, Cardillo A, Mazza M, Perri G, Iorfida M, Pruneri G, Goldhirsch A, Viale G (2012) Outcome of special types of luminal breast cancer. Ann Oncol 23(6):1428–1436. doi:10.1093/annonc/mdr461
29. Yu J, Dabbs DJ, Shuai Y, Niemeier LA, Bhargava R (2011) Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics. Am J Clin Pathol 136(1):88–97. doi:10.1309/AJCP7URIW0QETTAT
30. Hoff ER, Tubbs RR, Myles JL, Procop GW (2002) HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol 117(6):916–921. doi:10.1309/4NTU-N6K4-F8JF-EWRX
31. Altundag K, Ibrahim NK (2006) Aromatase inhibitors in breast cancer: an overview. Oncologist 11(6):553–562. doi:10.1634/theoncologist.11-6-553
32. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97(3):545–553. doi:10.1002/cncr.11083